Zhejiang Dayang Biotech Group Co., Ltd. Class A

As of June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A carries a market capitalization of 2.32B, placing it among publicly traded companies globally. Its enterprise value stands at 2.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A has 100.80M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A recorded 10.75M in income tax expense.

As of the close on October 23, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A's stock has declined approximately 22.77% over the past 52 weeks. The 50-day moving average sits at 22.61, while the 200-day moving average is 24.29.

As of June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A holds 397.61M in cash and equivalents against 452.34M in total debt, resulting in a net debt position of 61.89M. Total book value stands at 1.17B, with working capital of 1.44M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Dayang Biotech Group Co., Ltd. Class A paid dividends of 0.54 per share.

Zhejiang Dayang Biotech Group Co., Ltd. Class A's most recent stock split took place on June 26, 2026 with a 5:6 split ratio.